Kill a single bacterium in a lab dish and it is usually a straightforward matter of dose and contact time. Kill the same species once it has organized itself into a biofilm—a structured community stuck to a surface and encased in its own secretions—and the rules change entirely. This article explains why biofilms are so much harder to eliminate than free-floating ("planktonic") bacteria, what the peer-reviewed research actually shows about that resistance, and where two well-studied materials, silver and chitosan, fit into hygiene practice rather than into any claim of treatment or cure.

A Community, Not a Crowd

The modern understanding of biofilms owes a great deal to the microbiologist J.W. Costerton, whose work at the University of Montana's Center for Biofilm Engineering culminated in a widely cited 1999 review in Science, "Bacterial Biofilms: A Common Cause of Persistent Infections." Costerton and colleagues argued, based on electron microscopy and clinical sampling, that bacteria in nature and in the human body spend most of their time not as isolated swimming cells but as attached, cooperating communities. Subsequent work funded through the U.S. National Institutes of Health has been cited in support of the frequently repeated estimate that biofilms are implicated in a large majority of chronic bacterial infections in humans. That figure is an estimate drawn from clinical observation across many infection types, not a single controlled measurement, and it should be read as directional rather than precise.

What is measurable, and has been replicated many times in laboratory studies since the 1980s, is that bacteria growing in a biofilm can tolerate antimicrobial concentrations tens to hundreds of times higher than the same species growing freely in liquid culture. This is not because the bacteria have necessarily mutated into a resistant strain. It is because the community itself functions as a kind of fortification.

The Architecture of Resistance

Three mechanisms, each independently documented, explain most of this tolerance:

Together these mechanisms mean a biofilm is not simply "more bacteria." It is a different physiological state, and it is why hospital-acquired infections associated with catheters, implants, and chronic wounds are notoriously difficult to clear even with antibiotics that work well against the same organism in a blood culture.

Silver as an Antimicrobial Material: What the Evidence Shows

Silver's antimicrobial reputation predates modern microbiology. The Swiss botanist Karl Wilhelm von Nägeli described what he called the "oligodynamic effect"—the ability of very low concentrations of metal ions to inhibit microorganisms—in 1893. The proposed mechanism, refined over a century of subsequent chemistry and microbiology research, is that the silver ion (Ag+) binds to sulfur- and nitrogen-containing groups in bacterial proteins and enzymes, disrupts the cell membrane, interferes with the electron transport chain, and generates reactive oxygen species inside the cell. This is a broad-spectrum, physical-chemical mode of action rather than a single-target one, which is part of why bacteria have historically found it harder to evolve resistance to silver than to many antibiotics—though it is not impossible. A silver-resistance mechanism (the sil operon) was first characterized in a plasmid from Salmonella in the 1970s and has since been found, rarely, in other clinical isolates.

Chelated or complexed forms of silver bind the silver ion to a carrier molecule that releases it gradually rather than all at once. This is a formulation choice, well documented in materials chemistry literature, aimed at extending antimicrobial activity at the surface while reducing the free-ion concentration that can be irritating or cytotoxic to human tissue at higher doses.

It is important to be candid about the limits of this evidence in humans. Laboratory (in vitro) studies consistently show silver compounds killing or inhibiting a wide range of bacteria, including biofilm-forming species, on culture plates and biofilm models. Clinical evidence in real wounds and real patients is more mixed. A series of Cochrane systematic reviews of silver-containing wound dressings—including work by Vermeulen and colleagues (2007) and an update by Storm-Versloot and colleagues (2010)—found that despite clear in vitro antimicrobial activity, the trial evidence did not consistently demonstrate faster wound healing or better clinical outcomes compared with non-silver dressings. That gap between laboratory killing and clinical outcome is a recurring and honest theme in topical antimicrobial research generally, and it is one reason regulatory agencies distinguish carefully between an ingredient's demonstrated antimicrobial property and any claim that a finished product treats, cures, or prevents a disease.

Chitosan: A Structural Molecule From the Natural World

Chitosan is derived from chitin, the second most abundant natural polysaccharide on Earth after cellulose, found in the shells of crustaceans and the cell walls of many fungi. Deacetylating chitin yields chitosan, a polymer that carries a positive charge in mildly acidic conditions. That positive charge is the basis of its studied interaction with bacteria: bacterial cell membranes are generally negatively charged, and laboratory research published in journals such as Carbohydrate Polymers and the International Journal of Biological Macromolecules has shown chitosan binding to and disrupting bacterial membranes, and in some in vitro biofilm models, reducing biofilm biomass and interfering with the EPS matrix itself.

Chitosan also has a long research record as a hemostatic (bleeding-control) material—work supported in part by the U.S. Army Institute of Surgical Research led to chitosan-based battlefield dressings—because the same positive charge that attracts it to bacterial membranes also attracts it to negatively charged red blood cell membranes, promoting clot formation. That a molecule scavenged from shellfish shells has this dual physical property is, to this writer, a small but genuine reminder that the created order contains chemistry worth noticing long before any laboratory catalogued it.

As with silver, the caveat is real: most of the biofilm-disruption data for chitosan comes from in vitro models—bacteria grown on plastic or glass surfaces in a dish—and from some animal wound-healing studies. Robust, large-scale human clinical trials specifically measuring biofilm eradication on human skin are limited. Chitosan's antimicrobial and matrix-disrupting properties are well established as material science; what any specific finished product does on human skin in daily use is a separate, narrower question that manufacturers are not permitted to answer with disease claims unless it has gone through the regulatory process required of a drug.

Where This Leaves Hygiene Practice

None of the laboratory chemistry above changes the single most consistently validated intervention against bacterial spread: hygiene. The World Health Organization's hand hygiene guidance, drawing on decades of hospital infection-control research, has repeatedly found that measured hand hygiene compliance among healthcare workers hovers well below ideal levels—commonly cited studies put baseline compliance in many facilities under 50 percent—and that improving it measurably reduces healthcare-associated infection rates. A Cochrane review of hand-washing interventions for reducing respiratory illness (Jefferson and colleagues, updated over several cycles) found modest but real reductions in respiratory infection transmission associated with consistent hand hygiene, particularly in community and household settings.

This is worth dwelling on because it reframes the whole topic. Biofilm science explains why a colonized surface, wound, or device is hard to sterilize after the fact. It does not diminish the plainer, older wisdom that reducing bacterial load and interrupting transmission before a biofilm ever forms is the more reliable form of stewardship. Washing hands, cleaning wounds promptly, changing dressings, and maintaining clean surfaces in a home are unglamorous disciplines, but they are the ones with the deepest and most consistent evidence base. A chelated-silver and chitosan topical product used as part of a skin hygiene routine sits within that same practical tradition—a material chosen for documented physical and chemical properties, used as an adjunct to good hygiene practice, not as a substitute for a physician's diagnosis or treatment of an infection.

Patients and families who want to think seriously about this should feel free to ask their own physician or pharmacist how a given topical material's known chemistry applies to their specific situation. Understanding the difference between an ingredient's laboratory properties and a product's approved uses is part of informed consent, and having that conversation with a clinician you trust—rather than relying on a label alone—is a reasonable and responsible way to make decisions about one's own family's care.

The Honest Summary

Biofilm biology is one of the more genuinely humbling areas of microbiology: it shows that resistance is not always about a bacterium acquiring a resistance gene, but about bacteria behaving differently once they are together. Silver's antimicrobial chemistry has over a century of laboratory support and a real but more limited clinical evidence base in wound care specifically. Chitosan's antibacterial and matrix-interacting properties are well documented in vitro and supported by its separate, strong track record as a hemostatic material. Both are legitimate subjects of ongoing research. Neither is a substitute for medical diagnosis, antibiotic stewardship guided by a physician, or the basic hygiene practices that remain the best-evidenced way to reduce bacterial spread in daily life.

Key takeaway: Biofilms resist because bacteria in community behave differently than bacteria alone—and while silver and chitosan are genuinely studied antimicrobial materials, sound hygiene practice and a physician's guidance remain the best-evidenced defenses against bacterial infection.